Home 
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.8, p.577–581,2021
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.8, p.577–581,2021
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.122, No.8, p.577–581,2021 |
||
| Title: Serum metallothionein – a potential oncomarker? | ||
| Author: Z. Horakova, I. Starek | ||
| Abstract: INTRODUCTION: Metallothionein’s (MT) overexpression has been demonstrated immunohistochemically in neoplastic cells of many tumour types. Its elevation above the physiological level has been confirmed in circulation of their hosts. The results of studies dealing with the topic have been summarized to verify if this marker can be applied in the current oncologic practise. METHODS: The Pubmed and Google Scholar medical databases were reviewed for full-text articles focused on MT blood (plasma / serum) levels in patients with malignant tumours. RESULTS: In our review, after a precise selection, we included 8 prospective randomized trials encompassing 561 blood samples taken from patients with a large histopathological spectrum of malignancies. In general, significant differences in blood MT levels between oncological patients and healthy subjects were confirmed. No particular value of the MT level has been demonstrated to be unequivocally predictive of oncologic disease CONCLUSION: The results of our review suggest that although the elevation of MT in blood serum in patients with solid malignancy can be regarded as a promising tumour marker, the recommendations of its applicability in clinical practice require to be derived from further research on extended cohorts of patients (Tab. 1, Fig. 1, Ref. 49). |
||
| Keywords: metallothionein, tumour marker, solid tumour | ||
| Published online: 20-Jul-2021 | ||
| Year: 2021, Volume: 122, Issue: 8 | Page From: 577, Page To: 581 | |
| doi:10.4149/BLL_2021_092 |
||
|
|
 download file |
|